Kornimate/medical-research-clean huggingface dataset:
effects of different birthing balls used at the first stage of childbirth

Conditions: Labor Pain; Satisfaction, Patient; Labor Fast

Summary: the study aimed to determine the effects of different birthing balls used at the first stage of childbirth on birth outcomes and maternal satisfaction. randomized controlled, single-blind clinical study included a total of 180 pregnant women. the study included 3 groups (a: routine hospital care, b: spherical birthing ball, c: peanut ball). especially spherical birthing ball, were effective in reducing labor pain and facilitating faster rate of descent of the fetal head, and they increased maternal satisfaction.

the study aimed to determine the effects of different birthing balls used at the first stage of childbirth on birth outcomes and maternal satisfaction. randomized controlled, single-blind clinical study included a total of 180 pregnant women. the study included 3 groups (a: routine hospital care, b: spherical birthing ball, c: peanut ball). especially spherical birthing ball, were effective in reducing labor pain and facilitating faster rate of descent of the fetal head, and they increased maternal satisfaction. impact statement what is already known on this subject? labor pain and outcomes occurring during labor are known and expected situation. some non-pharmacological methods are applied to ensure that birth is easy and maternal satisfaction is high. what the results of this study add? there is no studies using the peanut ball and the spherical birth ball together. in our study, it was found that both balls are effective, but the spherical birth ball is more significant. what the implications are of these findings for clinical practice and/or further research? our study suggested that the spherical birth ball had effective on birth outcomes. future studies should be performed to investigate the effects of birth balls in the postpartum period, breastfeeding or prenatal period.

Eligibility criteria:
inclusion criteria: * primiparous * admitted to the delivery room for vaginal delivery * 38-40 week * being in the latent phase of labor * having no obstetric risks exclusion criteria: * undergo caesarean sections for various reasons * having obstetric risks

Keywords: birth ball labor pain satisfaction maternal fetal
mediterranean diet intervention among men at lbj hospital with prostate cancer

Conditions: Prostate Cancer

Summary: this study, we will build upon our prior work and test the feasibility of a mediterranean diet intervention for medically underserved men with prostate cancer seen at lbj hospital, a large safety net facility in harris county, tx.

primary objectives: to determine the feasibility of a mediterranean diet-based intervention adapted for underrepresented minority men with prostate cancer, defined based on the following process measures68: * enrollment (completion of 25 patient accrual within 2 years) * retention (completion of the study through the 6-month time point, with ≥80% defined as successful) * adherence (the percentage of completed study sessions and clinic visits, with ≥70% considered successful). secondary objectives: to determine changes due to the mediterranean diet intervention in the following measures: * mediterranean diet score (define using mepa i calculated using ffq data) * weight/bmi * qol (eq-5d-5l) * physical activity (ipas) * non-invasive biomarkers * gut microbiome * metabolomics

Eligibility criteria:
inclusion criteria: * histologically confirmed adenocarcinoma of the prostate that is localized based on metastatic workup ordered by the treating physician (which may include ct scan, bone scan, mri and/or other imaging). note that metastatic workup is not required for enrollment. * diagnosis within 12 months prior to enrollment or * currently managed on active surveillance, with initial biopsy being \<5 years from date of enrollment * self-identified hispanic and/or black/african american * patient at lbj hospital exclusion criteria: * special dietary requirements such that patient is unwilling to attempt dietary change * inability to complete a food record * unwillingness to participate in study activities * inability to keep appointments * food allergy prohibitive of a mediterranean diet, i.e. nuts allergy
fish collagen peptide food supplement on weight and body composition

Conditions: Weight Management; Food Complement

Summary: fish collagen hydrolysates or peptides orally administered have been investigated in recent clinical trials in human health. these peptides have been evaluated in various biological and medical fields including skin aging, osteoarticular apparatus, muscle and more recently in energy metabolism in both animals and humans. however, very few studies investigated the effect of fish collagen peptides on weight, body composition or glycemic response. recently, it has been shown that the consumption of fish collagen peptides (naticol®) limits weight gain and increase in fat mass in a mouse model made obese by a hyperlipidic diet. since these results have never been observed in humans, this pilot study proposes to answer this question.


Eligibility criteria:
inclusion criteria: * men in overweight (bmi between 25kg/m² and 30kg/m²) * aged from 18 and 60 years * having signed the informed consent form; * susceptible to follow the constraints generated by the study; exclusion criteria: * subject treated for type 1 or 2 diabetes, or for any other metabolic disorder (severe dyslipidemia: tg\> 3 g / l and total cholesterol\> 2.5 g / l); * subject with untreated and uncorrected high blood pressure; * subject with untreated or uncorrected dysthyroidism by drug therapy; * subject with a serious general illness that may prevent his or her ability to complete the trial or that could bias the results of the study; * subject consuming antibiotic treatment in the month prior to inclusion; * subject treated with steroidal anti-inflammatory drugs, anabolic steroids, anticoagulants or corticosteroids; * subject knowing allergy to fish or fish collagen; * subject taking any dietary supplement or drug that may interact with the results of the study or that could alter the bioavailability of the product under study; * subject following or having followed a low-calorie diet (energy intake \<1500 kcal / day) in the 3 months preceding inclusion and / or likely to undertake this diet during the test; * subject having lost more than 5% of his initial weight during the last 3 months; * subject following a special diet: eg. vegetarian, macrobiotic diet, high protein diet; * subject with diagnosed eating disorders (anorexia, bulimia); * subject with gastrointestinal malabsorption such as celiac disease, crohn's disease or lactose intolerance; * subject having undergone bariatric surgery; * subject with excessive alcohol consumption at more than 3 drinks a day ; * subject planning to modify his tobacco consumption (eg weaning) or his level of physical activity (significant increase) before the end of the intervention period; * subject having an aversion to the grapefruit aroma; * subject unable to understand or adhere to the protocol; * subject participating in another clinical study or exclusion period from another study;
the effect of sexual counseling based on plissit model to women undergoing open heart surgery on sexual function and sexual quality of life

Conditions: PLISSIT Model; Sexual Counselling

Summary: this study is about sexual counseling after cardiac surgery; it can contribute to the counseling planning of nurses and other health professionals regarding sexual problems that may occur after surgery. increasing the quality of life in the rehabilitation process after cardiac surgery and facilitating adaptation to life after surgery; but not enough.


Eligibility criteria:
inclusion criteria: * volunteering to participate in the research * being a woman * being over 18 years old * willingness to undergo open heart surgery * euroscore score ≤ 6 (low mortality risk due to cardiac surgery) * being sexually active * absence of sexual health problems in the spouse * ability to communicate verbally and be literate * women without neurological or psychiatric disorders * knowing turkish exclusion criteria: * unwillingness to participate in the research * euroscore score \>6 (high risk of mortality) * not being sexually active * having a diagnosed sexual health problem in the spouse * women with neurological and psychiatric disorders
neoadjuvant tucidinostat and exemestane in early breast cancer

Conditions: Breast Cancer

Summary: this study is to evaluate the efficacy of tucidinostat combined with exemestane as neoadjuvant strategy in estrogen receptor-positive early breast cancer patients and explore the genetic model which can predict neoadjuvant endocrine therapeutic results.

this study is to evaluate the efficacy of tucidinostat combined with exemestane as neoadjuvant strategy in estrogen receptor-positive early breast cancer patients.this study will recruit 30 patients. the 30 patients will receive 25 mg exemestane qd for 26 weeks. tucidinostat will be prescribed 30 mg biw from week 3 to week 26. during neoadjuvant treatment biopsy, ceus and mri will be perfomed according to protocol to evaluate the therapeutic results. genetic testing will also be performed before and after neoadjuvant treatment to explore the predictive value. mri evaluated orr is primary end point. ceus evaluated orr, pcr, ae and rcb are secondary end point.

Eligibility criteria:
inclusion criteria: 1. written informed consent must be signed； 2. eastern cooperative oncology group performance status: 0\~1; 3. histological confirmation of estrogen receptor (er) positive and her 2 negative invasive breast cancer; 4. age ≥18 years old； 5. no distant metastatic disease； 6. the disease condition is stage ii or stage iii; 7. laboratory exam criteria for enrollment: hgb≥10g/dl, wbc≥4,000/mm3, plt≥100,000/mm3, got, gpt, alp≤2 times uln, tbil, ccr≤1.5 times uln. exclusion criteria: 1. patients who are pregnant or lactating at the time of randomization or refuse to contraception. 2. patients who received organ transplantation (include bone marrow autologous transplantation and stem cell transplantation). 3. patients who have other malignant diseases within 5 years, except for cured skin basal cell carcinoma, flat cell carcinoma or cervical carcinoma in situ 4. patients with psychiatric disorder, peripheral or central nerve system disease or any disorder, which compromises ability to give informed consent or participate in this study. 5. patients with sever hepatic, renal,cardiovascular, respiratory, digestive diseases or uncontrolled diabetes. 6. patients who had myocardial infarction in the past 12 months. 7. patients who participate in other clinical trail. 8. patients who allergy to goserelin, leuprorelin, tucidinostat or aromatase inhibitor.

Keywords: tucidinostat estrogen receptor-positive neoadjuvant endocrine therapy
a study of belzutifan (mk-6482) in combination with palbociclib versus belzutifan monotherapy in participants with advanced renal cell carcinoma (mk-6482-024/litespark-024)

Conditions: Renal Cell Carcinoma

Summary: the purpose of this study is to evaluate the efficacy and safety of belzutifan monotherapy and belzutifan plus palbociclib combination therapy in participants with advanced clear-cell renal cell carcinoma (ccrcc) who experienced disease progression on or after receiving prior therapy. part 1 will establish the safety of belzutifan plus palbociclib and determine a recommended dosage of palbociclib for the combination therapy by ascending dose escalation. part 2 will evaluate the efficacy and safety of belzutifan plus palbociclib at the dosage level determined in part 1.


Eligibility criteria:
inclusion criteria: * has a histologically confirmed diagnosis of unresectable stage iv (per american joint committee on cancer \[ajcc\], 8th edition) rcc with clear-cell component * has had disease progression on or after having received at least 2 systemic treatments for unresectable stage iv rcc with prior anti-programmed cell death 1 ligand 1 (pd-1/l1) and a vascular endothelial growth factor-tyrosine kinase inhibitor (vegf-tki) in sequence or in combination * has measurable disease per recist 1.1 as assessed by the investigator and verified by blinded independent central review (bicr) * has recovered from all aes due to previous therapies exclusion criteria: * has hypoxia, requires intermittent supplemental oxygen, or requires chronic supplemental oxygen * has a known additional malignancy that is progressing or has required active treatment within the past 3 years * has known central nervous system (cns) metastases and/or carcinomatous meningitis * has clinically significant cardiac disease * has moderate to severe hepatic impairment * has a known history of human immunodeficiency virus (hiv) infection * has a history of hepatitis b (hbv) or known active hepatitis c (hcv) infection * has received prior treatment of belzutifan or palbociclib * has received prior radiotherapy ≤2 weeks prior to first dose of study intervention. participants must have recovered from all radiation-related toxicities and not require corticosteroids * has had major surgery ≤3 weeks prior to first dose of study intervention * has received colony-stimulating factors (eg, granulocyte colony-stimulating factor \[g-csf\], granulocyte-macrophage colony-stimulating factor \[gm-csf\], or recombinant erythropoietin \[epo\]) ≤28 days prior to the first dose of study intervention

Keywords: programmed cell death ligand 1 (pd-l1) hypoxia inducible factor 2 alpha (hif-2 alpha) hypoxia inducible factor 2α (hif-2α) renal cell carcinoma (rcc) kidney cancer
implementing mhealth for schizophrenia in community mental health settings

Conditions: Schizophrenia

Summary: randomized control trial examining two mhealth intervention strategies.

the investigators will conduct a multi-site site hybrid type iii effectiveness/implementation study in washington state. the study involves a systematic head-to-head comparison between external facilitation (ef) and internal facilitation (if) implementation models applied to the focus mhealth intervention.

Eligibility criteria:
all participants need to be receiving clinical care at participating clinics who have partnered with the research team for this study. inclusion: 1. chart diagnosis of ssd (i.e., schizophrenia, schizoaffective disorder, schizotypal disorder, delusional disorder, or schizophreniform disorder; 2. 18 years or older; 3. english-speaking; 4. own a smartphone that can support focus and active data plan. exclusion: 1. used focus in the past; 2. plan to move or discontinue services at participating clinics in the upcoming 6 months.
tracking wound infection with smartphone technology

Conditions: Surgical Site Infection

Summary: this study aims to evaluate if a smartphone-delivered tool can help assess for wound infections, and if this improves access to care and results in earlier treatment. participants will be randomised to one of two groups. the intervention group will receive the smartphone-delivered wound assessment tool (swat), to access if they have concerns about their wound. the trial period is 30 days.

surgical site infection (ssi) is defined by the centre for disease control and prevention (cdc) as an infection in the skin and soft tissues of a surgical wound, within 30 days of the operation. it is a common problem, and complicates 2-10% of general surgery operations. the majority of cases are diagnosed outside of hospital and can be treated with oral antibiotics. interest in the use of technology in medicine is increasing, with the potential that more advanced technology will help facilitate communication between clinicians and patients, aid in the assessment of patients, and improve clinical decision making. over two-thirds of people now own smartphones, and regularly use them to access the internet. the investigators wish to use a smartphone delivered questionnaire to help assess ssi and see if this improves access to care and time to treatment. the investigators will be recruiting emergency surgery patients with smartphones at the royal infirmary and western general hospitals in edinburgh. participants will be divided into two groups. one group will receive the wound assessment tool, if they are concerned about their wound, they can use the tool to answer a series of questions. if their answers suggest ssi, a clinician will contact them to advise further assessment and treatment. the participants will also be asked to respond to the tool three times during the trial (to collect responses from those without symptoms), and upload photos of their wounds to a secure database. the second group of participants will receive normal post-operative care. after 30 days, participants will have a follow-up consultation, to determine if they have had a wound infection (this can be via telephone or face-to-face, according to participant preference). they will also answer questions about their experience of the study, and use of services.

Eligibility criteria:
inclusion criteria: * emergency abdominal surgery patients * smartphone owners * able to give valid consent exclusion criteria: * significant visual impairment
valvular heart disease registry study in second affiliated hospital of zhejiang university

Conditions: Valvular Heart Disease

Summary: we design a prospective, observational cohort study to provide contemporary information on the prevalence, characteristics, risk stratification，cost-effective ,treatments and prognosis of chinese hospitalised adult patients with valvular heart disease.

valvular heart disease (vhd) is becoming more and more frequent with the aging, which has brought a heavy burden to the world. however, the prevalence and prognosis of valvular heart disease are not so clear, especially in the developing countries such as china etc. because of the slow and progressive nature of vhd, symptoms might not be too severe to be diagnosed on time. our retrospective survey (int j cardiol. 2016 nov 25) indicated that severe valvular diseases are very common in china. hence, we design a prospective, observational cohort study to provide contemporary information on the prevalence, characteristics, risk stratification，cost-effective ,treatments and prognosis of chinese hospitalised adult patients with valvular heart disease.

Eligibility criteria:
inclusion criteria: hospitalized patients over 18 years old meet one of the following conditions. 1. moderate or above valvular heart disease as defined by echocardiography: 1.1 aortic stenosis, moderate or above, or valve area ≤1.5cm2, or maximal jet velocity ≥3.0m/sec, or mean pressure gradient ≥20mmhg, 1.2 aortic regurgitation, moderate or above, or jet width ≥25% of left ventricular outflow tract, or regurgitant volume ≥30ml/beat, or regurgitant fraction ≥30%, 1.3 mitral stenosis, moderate or above, or valve area ≤2.0cm2, 1.4 mitral regurgitation, moderate or above, or effective regurgitant orifice ≥0.2cm2, or regurgitant volume ≥30ml/beat, or regurgitant fraction ≥30%, 1.5 tricuspid stenosis, moderate or above, or valve area ≤1.0cm2, 1.6 tricuspid regurgitation, moderate or above, or central jet area ≥5.0cm2, 1.7 pulmonic stenosis, moderate or above, or maximal jet velocity \>4m/sec, 1.8 pulmonic regurgitation, moderate or above, 2. patients who had undergone any operation on a cardiac valve (percutaneous balloon commissurotomy, valve repair, valve replacement, transcatheter aortic valve implantation), 3. diagnosis of endocarditis as assessed by duke criteria. exclusion criteria: 1. patients cannot be followed up for any reasons. 2. patients in critical condition may be die in one year. 3. patients have been enrolled in this study.
effectiveness evaluation in thrombus aspiration in patients with stemi and high thrombotic load

Conditions: STEMI

Summary: this study intends to evaluate thrombus on the basis of different methods for evaluating thrombus load the effect of aspiration on the prognosis of stemi patients with high thrombotic load provide a basis for the standardized use of aspiration; at the same time, discover the best benefit groups for thrombus aspiration


Eligibility criteria:
inclusion criteria: * (1) age ≥ 18 years; (2) voluntary signing of informed consent; (3) onset of 12 hours stemi patients who underwent pci reperfusion therapy within time; (4) the guidewire passes through the lesion and the blood heavy embolism load (timi thrombus classification ≥ 3). exclusion criteria: * (1) hemodynamics is unstable or there is cardiogenic shock; (2) after thrombolytic therapy; (3) the expected survival time is less than 6 months due to non-cardiac diseases; (4) past trips coronary artery bypass graft patients; (5) participate in other drug and device research within 30 days; (6) before surgery, clear active gastrointestinal bleeding or other contraindications for taking dual antiplatelet drugs (7) patients deemed unsuitable for enrollment by other researchers
live classical music and the response to the disease and its evolution in patients with chronic renal failure

Conditions: Chronic Kidney Diseases; Haemodialysis

Summary: people are most vulnerable to anxiety when faced with life-threatening situations such as illness, medical treatments and surgeries. when a person becomes ill, he and his family must face a series of changes in their life habits, must cope with admissions, aggressive treatments and endure physical pain. these changes can generate an unfavorable state of mind to face the disease, which sometimes worsens the previous clinical situation. the direct effect of music has been studied in different pathologies during the last years. the proposed research sought to provide information on the influence of classical music listened to live and in situ in the hospital, and the response to the disease and its evolution, in patients with chronic renal failure. for this purpose, the effect of live music performances in hemodialysis rooms was analyzed and changes in the patients' mood and quality of life were observed. changes in vital sign recording were also observed, all of which were assessed before and after the interventions. finally, we checked if there were any changes in the variables described as confounders (kt/v-albumin-hemoglobin-blood pressure-consumption of psychotropic drugs and analgesics), which could be attributable to listening to music.to test the effect in patients with chronic renal failure, live classical music was listened to in the hospital, as an adjuvant to treatment during haemodialysis processes. ninety patients participated in 2 groups, the intervention group that listened to music during haemodialysis sessions and the control group that continued with their usual treatment. changes in anxiety and mood were analyzed by means of the quality of life questionnaire (had) and quality of life by spheres with the kdqol-sf questionnaire, before and after the intervention in both groups. to test the effect in patients with chronic renal failure, live classical music was listened to in the hospital, as an adjuvant to treatment during haemodialysis processes. ninety patients participated in 2 groups, the intervention group that listened to music during haemodialysis sessions and the control group that continued with their usual treatment. changes in anxiety and mood were analyzed by means of the quality of life questionnaire (had) and quality of life by spheres with the kdqol-sf questionnaire, before and after the intervention in both groups.


Eligibility criteria:
inclusion criteria: * patients over 18 years of age. * signed informed consent. * to be more than 3 months in the chronic hd program. exclusion criteria: * inability to listen to music. * inability to answer the surveys. * failure to sign informed consent to participate. * under 18 years of age. * hospital admissions for more than 4 weeks or in the last two weeks of the intervention.